Acne

This article will discuss insights from research studies and offer specialized guidance aimed at dermatologists in hopes of fostering patient adherence in acne management.

Researchers found that high levels of AST and ALT in patients with acne taking oral isotretinoin was low in incidence.

In this week’s Pointers With Portela, the 208SkinDoc reviews 7 different methods to treat acne without isotretinoin.

The pilot study explored the use of double-conjugated retinoid serum used in combination with exfoliating peel pads.

In this week’s Pointers With Portela, the 208SkinDoc reveals his 5 essential acne care tips.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in acne this year.

The most prevalent psychological disorder among patients was anxiety.

Researchers have explored whether the adverse effects of tazarotene are exacerbated during the colder winter months and whether there is variation in treatment efficacy and tolerability between cold vs warm seasons.

Linda Stein Gold, MD, reviewed recent studies of various topical retinoids and their ability to decrease atrophic scars during the 2023 ARM Yourself With Knowledge webinar.

Baldwin reviewed inflammatory bowel disease, depression, and pregnancy during the 2023 ARM Yourself With Knowledge webinar.

Click here to answer this week's acne poll.

The technology combines the irradiation of two wavelengths at 10,600 nm and 1540 nm.

Despite how widely used these acids often are, there is still a lack of general consensus for which are the most effective in patients with acne-prone skin.

New technologies such as the 1726-nm laser and pneumatic assisted broad band light are emerging treatments in acne.

Dr Adelaide A. Hebert discusses pediatric acne management, early onset trends, and the future of acne care.

Adelaide A. Hebert, MD, FAAD, shares her commentary on advancements in acne management, highlighting advancements in the pathophysiology, benefits of multimodal treatment approaches, and the role of retinoids.

The Sun Pharma survey included 1003 respondents with mild to moderate acne.

Allison Arthur, MD, discussed the importance of tailoring a treatment plan for adult women with acne vulgaris that best suits their lifestyle and current needs.

A post hoc analysis evaluated the safety, efficacy, and tolerability of IDP-126 gel in Black patients with moderate to severe acne, of which there are limited data and literature describing its outcomes in this patient population.

Christopher Bunick, MD, PhD, reviews Cabtreo’s recent FDA approval and what the new triple-combination gel means for acne patients.

The US Food and Drug Administration has approved IDP-126 gel for patients with acne.

Hilary Baldwin, MD, offers her insights and hypotheses regarding the future of over-the-counter and pharmaceutical treatments, emphasizing the evolving landscape and the potential role of targeted microbiome-based approaches in the management of acne.

Hilary Baldwin, MD, shares her thoughts on the importance of the Science of Skincare summit and emphasizes the significance of this event in disseminating clinically sound insights into over-the-counter active ingredients.

Overall, acne events were mild or moderate and did not cause patients to discontinue ruxolitinib cream treatment.

Aaron Farberg, MD, and Shanna Miranti, MPAS, PA-C, discuss the upcoming approvals of nivolumab and IDP-126.